Gudrun Schleiermacher

This study compares ex vivo short-term, organoid, and PDX drug screening methods in neuroblastoma, finding ex vivo screens are faster and more consistent with in vivo results.

The paper introduces a PDX platform for pediatric cancers, providing in vivo drug testing models and molecular data to aid in therapy development.

This study shows that ATRX mutation type affects chromatin response to retinoic acid in neuroblastoma, influencing differentiation and therapeutic response.

The paper identifies transcriptional noise as a driver of cancer treatment adaptation through AP-1 and KDM5-mediated chromatin rewiring in neuroblastoma and hepatoblastoma.

This study identifies three modes of plasticity in neuroblastoma that shape tumour evolution under selective pressures and therapy resistance.

This study demonstrates that reduced representation bisulfite sequencing of cell-free DNA can accurately classify pediatric solid tumors with high sensitivity.

The paper introduces QuantumClone, a method for clonal reconstruction in cancer that accounts for variant allele frequencies and genotypes, and applies it to neuroblastoma samples to identify recurrently altered pathways in different clonal populations.